D&D Pharmatech Inc. (KOSDAQ:347850)

South Korea flag South Korea · Delayed Price · Currency is KRW
92,400
+3,600 (4.05%)
At close: Feb 27, 2026
Market Cap4.02T +559.7%
Revenue (ttm)8.36B +2.2%
Net Income-34.76B
EPS-845.57
Shares Out43.54M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume825,776
Average Volume724,983
Open89,200
Previous Close88,800
Day's Range88,900 - 94,300
52-Week Range10,125 - 113,700
Betan/a
RSI55.20
Earnings DateMar 20, 2026

About D&D Pharmatech

D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson’s and Alzheimer’s diseases. The company is also involved in the development of TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 347850
Full Company Profile

Financial Performance

Financial Statements